A Johnson & Johnson exercise in creative problem solving has paid off for doctors and patients who rely on its ovarian cancer drug Doxil, availability of which has been uncertain for years. Its Janssen unit has accumulated a significant supply after assuming manufacturing at Boehringer Ingelheim plant that otherwise was closed down at the end of the year.
One hundred Irish Pfizer jobs once tapped for chopping are now safe, and the company's off-patent meds, like Lipitor, are the saviors.
Sun Pharmaceutical, which has touted itself as having the skills to fix quality problems at Ranbaxy Laboratories, is recalling two more lots of an antidepressant. The recall is its third since its April announcement that it would buy its troubled competitor in a $3.2 billion deal.
GlaxoSmithKline is under pressure from not one, but two regulatory bodies to get problems under control at a flu vaccine plant in Canada. After the FDA handed the company a warning letter late last month, Health Canada now says the pharma giant has a month to lay out a plan for resolving issues there.
GlaxoSmithKline, responding to an FDA warning letter sent to the plant that produces its FluLaval and other influenza vaccines for the U.S. and Canada, said it expects to be on track to produce more than 30 million doses for the upcoming flu season. But the experience of other drugmakers suggests that even a small hiccup in producing a vaccine for a crucial cycle can be significant to a drugmaker's top and bottom lines.
Teva CFO Eyal Desheh says the generic giant was built in bits and pieces, picking up a bunch of manufacturing plants in the process that it no longer needs. So the company will close half of its manufacturing facilities over the next 5 years as part of its plan to get more focused and more efficient.
Some drugmakers--like Dr. Reddy's Laboratories--are wondering whether manufacturing troubles could be reduced by taking human workers out of the equation.
India's Wockhardt recently dodged a bullet at home when the country's Drug Controller General lifted a production ban there. But now, it may be in more hot water in an even bigger market.
While other drugmakers are closing plants in the face of patent losses and revenue challenges, Roche is steadily expanding its manufacturing network.
Hospira, which had to cede market share when its own manufacturing issues led to extensive remediation at its key U.S. plant, is now benefiting from someone else's missteps.